Fisher & Paykel Healthcare (FPH) Stock Overview
Designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FPH passed our risk checks.
FPH Community Fair Values
Create NarrativeSee what 34 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Fisher & Paykel Healthcare Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$36.80 |
| 52 Week High | NZ$41.40 |
| 52 Week Low | NZ$34.61 |
| Beta | 0.91 |
| 1 Month Change | 0.27% |
| 3 Month Change | -7.42% |
| 1 Year Change | 3.37% |
| 3 Year Change | 36.55% |
| 5 Year Change | 8.55% |
| Change since IPO | 8,077.78% |
Recent News & Updates
FPH: Upgraded Guidance And Sector Perform Rating Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare by about NZ$0.10 to reflect slightly higher discount rate assumptions, while also acknowledging improved profit margin expectations and recent upgrades in Street price targets, including a move to NZ$36 at one major firm. Analyst Commentary Bullish Takeaways Bullish analysts point to the company’s updated guidance as a key reason for shifting to a more neutral stance, seeing this as support for the revised fair value and the NZ$36 price target.If EPS Growth Is Important To You, Fisher & Paykel Healthcare (NZSE:FPH) Presents An Opportunity
Apr 18
FPH: Refreshed Guidance And Sector Perform Rating Will Shape Measured Future Expectations
Analysts have trimmed the fair value estimate for Fisher & Paykel Healthcare to about NZ$40.69 from NZ$40.89, citing improved company guidance and a higher NZ$36 Street price target as support for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgraded company guidance as support for moving to a more neutral stance on the shares, which they see as better aligning expectations with current execution.FPH: Updated Guidance And Sector Perform Rating Will Shape Balanced Future Expectations
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare to NZ$40.89 from NZ$41.12. The modest shift reflects updated assumptions for the discount rate, profit margin and future P/E, following recent guidance and a price target move to NZ$36 from NZ$31 in Street research.FPH: Refreshed Guidance And Sector Perform Upgrade Will Support Fair Value View
Narrative Update Analysts have lifted their price target for Fisher & Paykel Healthcare to NZ$41.12 from NZ$40.81, citing refreshed guidance and recent Street research that includes an upgrade to Sector Perform with a higher NZ$36 target. Analyst Commentary Bullish analysts see the refreshed guidance as a key reason to reassess Fisher & Paykel Healthcare, with one recent upgrade moving the stock to Sector Perform and lifting the price target to NZ$36 from NZ$31.Recent updates
FPH: Upgraded Guidance And Sector Perform Rating Will Support Bullish Repricing
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare by about NZ$0.10 to reflect slightly higher discount rate assumptions, while also acknowledging improved profit margin expectations and recent upgrades in Street price targets, including a move to NZ$36 at one major firm. Analyst Commentary Bullish Takeaways Bullish analysts point to the company’s updated guidance as a key reason for shifting to a more neutral stance, seeing this as support for the revised fair value and the NZ$36 price target.If EPS Growth Is Important To You, Fisher & Paykel Healthcare (NZSE:FPH) Presents An Opportunity
Apr 18FPH: Refreshed Guidance And Sector Perform Rating Will Shape Measured Future Expectations
Analysts have trimmed the fair value estimate for Fisher & Paykel Healthcare to about NZ$40.69 from NZ$40.89, citing improved company guidance and a higher NZ$36 Street price target as support for the updated view. Analyst Commentary Bullish Takeaways Bullish analysts point to the upgraded company guidance as support for moving to a more neutral stance on the shares, which they see as better aligning expectations with current execution.FPH: Updated Guidance And Sector Perform Rating Will Shape Balanced Future Expectations
Analysts have trimmed their fair value estimate for Fisher & Paykel Healthcare to NZ$40.89 from NZ$41.12. The modest shift reflects updated assumptions for the discount rate, profit margin and future P/E, following recent guidance and a price target move to NZ$36 from NZ$31 in Street research.FPH: Refreshed Guidance And Sector Perform Upgrade Will Support Fair Value View
Narrative Update Analysts have lifted their price target for Fisher & Paykel Healthcare to NZ$41.12 from NZ$40.81, citing refreshed guidance and recent Street research that includes an upgrade to Sector Perform with a higher NZ$36 target. Analyst Commentary Bullish analysts see the refreshed guidance as a key reason to reassess Fisher & Paykel Healthcare, with one recent upgrade moving the stock to Sector Perform and lifting the price target to NZ$36 from NZ$31.FPH: Improved Guidance And Rating Upgrade Will Support Fairly Valued Outlook
Analysts have lifted their NZ$ fair value estimate for Fisher & Paykel Healthcare from NZ$39.15 to NZ$40.81, citing improved company guidance and a recent upgrade in Street price targets as key supports for the higher range of outcomes. Analyst Commentary Bullish Takeaways Bullish analysts see the higher company guidance as a key support for the uplift in fair value to NZ$40.81, suggesting more confidence in the near term earnings outlook than previously reflected in models.Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) Shareholders Might Be Looking For Exit
Feb 15FPH: Updated Guidance And Dividend Increase Will Support Fairly Valued Outlook
Analysts have made slight adjustments to their price target for Fisher & Paykel Healthcare, keeping fair value broadly unchanged at about $39.15 per share. They have updated inputs such as the discount rate and assumed future P/E to reflect refreshed views on risk and long-term valuation assumptions.FPH: Updated Guidance And Dividend Policy Will Support Fairly Valued Returns
Analysts have made only a marginal adjustment to their price target for Fisher & Paykel Healthcare, reflecting small tweaks to assumptions around the discount rate, long term revenue growth, profit margin and future P/E, rather than any major shift in their overall view. What's in the News Fisher & Paykel Healthcare updated full year 2025 guidance, with operating revenue now expected in a range of about $2.17b to $2.27b, compared with the prior range of about $2.15b to $2.25b (Key Developments).FPH: Dividend And Earnings Guidance Will Support Fairly Valued Future Returns
Analysts have trimmed their price target on Fisher & Paykel Healthcare slightly, citing updated assumptions around discount rate, long run revenue growth, profit margin and future P/E that together point to a fair value of about A$39.15 compared with A$39.33 previously. What's in the News Directors approved an interim dividend of 19.0 cents per ordinary share, compared with 18.5 cents per share in the first half of the prior year, with full New Zealand imputation credit attached (Key Developments).Here's Why Fisher & Paykel Healthcare (NZSE:FPH) Has Caught The Eye Of Investors
Dec 18FPH: Dividend Increase And Earnings Upgrade Will Support Fair Future Returns
Analysts have slightly raised their price target on Fisher & Paykel Healthcare to $NZD 39.33, reflecting modestly lower discount rate assumptions and a slightly higher future P/E multiple, partly offset by a small downward revision to projected profit margins. What's in the News Directors approved an increased interim dividend of 19.0 cents per ordinary share, up from 18.5 cents in the prior first half, to be paid on 16 December 2025 with a record date of 4 December 2025 (company announcement).FPH: Dividend Lift And Profit Outlook Will Support Fair Future Returns
Analysts have raised their price target for Fisher & Paykel Healthcare by roughly NZ$2. This reflects expectations of slightly higher long term profitability, modestly lower growth assumptions, and a marginally higher discount rate.Fisher & Paykel Healthcare Corporation Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 28FPH: Fair Value Will Stay Stable Amid Slightly Higher Discount Rate
Analysts have raised their price target for Fisher & Paykel Healthcare from $36.61 to $37.26. They cite slightly higher projected revenue growth along with modest improvements in the profit margin outlook.At NZ$36.64, Is Fisher & Paykel Healthcare Corporation Limited (NZSE:FPH) Worth Looking At Closely?
Nov 18FPH: Fair Value Assessment Will Remain Steady With Minor Discount Rate Adjustment
Analysts have marginally increased their price target for Fisher & Paykel Healthcare to $36.61. This reflects minor adjustments in company fundamentals and updated discount rate assumptions.Analysts Hold Price Target for Fisher and Paykel Healthcare as Valuation Inputs Remain Stable
Analysts have maintained their price target for Fisher & Paykel Healthcare at $36.61 per share, citing stable forecasts for discount rate, revenue growth, profit margin, and forward price-to-earnings ratios. Minimal changes were observed in the underlying model inputs.Aging Demographics And Product Upgrades Will Expand Respiratory Care
Analysts have modestly increased their price target for Fisher & Paykel Healthcare from $36.06 to $36.61 NZD, reflecting updated forecasts for slightly higher revenue growth and improved profitability expectations. Valuation Changes Fair Value Estimate has risen slightly from NZ$36.06 to NZ$36.61 per share.Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Oct 07Aging Demographics And Product Upgrades Will Expand Respiratory Care
Fisher & Paykel Healthcare's consensus revenue growth and future P/E forecasts both saw only marginal improvements, underpinning the slight increase in the analyst price target from NZ$35.68 to NZ$36.06. What's in the News Fisher & Paykel Healthcare announced an ordinary unfranked dividend of NZD 0.28235294 per share for the six months ended March 31, 2025, payable on July 4, 2025.Here's Why Fisher & Paykel Healthcare Corporation Limited's (NZSE:FPH) CEO Might See A Pay Rise Soon
Aug 14These 4 Measures Indicate That Fisher & Paykel Healthcare (NZSE:FPH) Is Using Debt Safely
Jul 30Be Wary Of Fisher & Paykel Healthcare (NZSE:FPH) And Its Returns On Capital
Jun 12
New Product Launches And Capacity Expansion Fuel Optimism Amid Margin Pressure And Growth Uncertainty
Diversification with new products and increased manufacturing capacity may drive revenue, but risks include overestimating demand and resulting profit margin pressures.Shareholder Returns
| FPH | NZ Medical Equipment | NZ Market | |
|---|---|---|---|
| 7D | 2.3% | -0.2% | 0.9% |
| 1Y | 3.4% | -28.4% | 5.0% |
Return vs Industry: FPH exceeded the NZ Medical Equipment industry which returned -28.4% over the past year.
Return vs Market: FPH underperformed the NZ Market which returned 5% over the past year.
Price Volatility
| FPH volatility | |
|---|---|
| FPH Average Weekly Movement | 4.7% |
| Medical Equipment Industry Average Movement | 10.4% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in NZ Market | 8.0% |
| 10% least volatile stocks in NZ Market | 2.8% |
Stable Share Price: FPH has not had significant price volatility in the past 3 months compared to the NZ market.
Volatility Over Time: FPH's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1934 | 7,412 | Lewis Gradon | www.fphcare.com |
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. It provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. The company also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation.
Fisher & Paykel Healthcare Corporation Limited Fundamentals Summary
| FPH fundamental statistics | |
|---|---|
| Market cap | NZ$21.25b |
| Earnings (TTM) | NZ$437.00m |
| Revenue (TTM) | NZ$2.16b |
49.5x
P/E Ratio10.0x
P/S RatioIs FPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FPH income statement (TTM) | |
|---|---|
| Revenue | NZ$2.16b |
| Cost of Revenue | NZ$790.40m |
| Gross Profit | NZ$1.37b |
| Other Expenses | NZ$930.90m |
| Earnings | NZ$437.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
May 25, 2026
| Earnings per share (EPS) | 0.74 |
| Gross Margin | 63.38% |
| Net Profit Margin | 20.25% |
| Debt/Equity Ratio | 3.1% |
How did FPH perform over the long term?
See historical performance and comparisonDividends
1.2%
Current Dividend Yield58%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/04 13:12 |
| End of Day Share Price | 2026/05/04 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fisher & Paykel Healthcare Corporation Limited is covered by 23 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Saul Hadassin | Barrenjoey Markets Pty Limited |
| Lyanne Harrison | BofA Global Research |
| Shane Storey | Canaccord Genuity |